Sclc Case Study Nursing

The aim of this study is to provide a detailed account of the nursing care for a patient who is experiencing a breakdown in health. One aspect of their care will be discussed in relation to the nursing process. The model used to provide an individualised programme of care will be discussed and critically analysed.

1. The nurse is asked to implement a new, complex, and invasive procedure and is concerned that this may violate the state’s nurse practice act.

CHIEF COMPLAINT: This is a post op note from a procedure performed July 21, 2015 by David Lin, MD.

Currently, locoregional therapies play an important role in the treatment of patients awaiting LT. For patients listed within the (stage T2-HCC), a delay of LT over 6-12 months without bridging treatment is a well-recognized risk factor for tumor progression and dropout from the list or interval dissemination with post-transplant tumor recurrence. (Freeman RB et al., 2006).

Implementing Health Information System (HIS) in health care is viewed as an effective strategy to deliver safe and integrated patient care. After the introduction of incentive payments to meaningful use of Electronic Health Record (EHR) many health care organizations are actively undergoing the process of HIS implementation or its update to deliver quality care (Boswell, 2011). It is crucial to analyze the factors that will lead to successful implementation of HIS thereby the organizations not only save money but also choose to adopt the technology that is appropriate.

For all patients with ALL, both systemic therapy and CNS-directed therapy are required. Systemic chemotherapy involves a combination of intravenous and oral medications, with

Depending on the stage at presentation, the primary management strategies for patients with MIBC consist of surgery and/or chemotherapy. The cure rates for stage II cancers treated with surgery alone are high. A key challenge in the management of MIBC is that the majority of patients have locally advanced disease (Stages III to IV) at first presentation. There is a continuum between NIMIBC and MIBC, with the advanced cases usually associate with less-differentiated histology and aneuploidy, with common sites of metastasis include regional lymph nodes, bone, lung, skin and liver{Kaufman, 2006 #782}. From the low cure rates achieved with radical cystectomy, there is strong evidence that UBC, from the outset, is a systemic disease{Kaufman, 2006 #782}. The limitations of local treatment are

The SEER is a population-based cancer database by National Cancer Institute. The SEER 13 represents approximately 14% of the population of the United States and includes 13 cancer registries - San Francisco-Oakland, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle (Puget Sound region), Utah, Atlanta, San Jose-Monterey, Los Angles, Alaska Natives, and rural Georgia. High quality data are collected from hospitals and cancer treatment centers. The database includes primary tumor site, staging, patient demographics, treatment modality and survival statistics (10). We selected adult patients (≥ 18 years) diagnosed with first primary HCC between January 1992 and December 2011. We excluded cases diagnosed at autopsy and those lost to

This was a prospective study conducted on newly-diagnosed operable NSCLC patients enrolled between January 2006 and December 2010. NSCLC patients with previous or coexisting cancer other than NSCLC, treated with radiotherapy or chemotherapy, or had other diseases suspected of influencing serum CRP or plasma fibrinogen levels were excluded from the study. Overall, a total of 153 patients were studied at a tertiary hospital in China. The study was approved by the hospital’s institutional review board and written consent was obtained from all the participating patients.

Although there is no established treatment for PCNSL, therapeutic protocols involving treatment with high dose methotrexate followed in some cases by the general WBRT were taken and given relatively favorable results. These protocols can not be used to treat several patients either reduced the overall condition of the patient or a number of other complications. There is also the dilemma when these protocols that the patient may develop leukoencephalopathy, especially an elderly patient are used. Although generally reserved for use as GKS treatemtn or provisional in patients with this type of tumor extent, there are conditions in which we perform less invasive technique in patients with PCNSL. Here we summarize the results of our cases and assess the efficiency and effectiveness of GKS in treating HIV patients.

Sarcomas are rare and considerably heterogeneous malignant tumours with a plethora of different tumour behaviours, corresponding to almost 1.5% of all adult malignancies2. For most sarcoma subtypes the mainstay of management for localized disease is complete surgical resection with or without radiation. However, despite optimal treatment about 50% of patients with high grade tumours will develop metastatic disease. The outcome for patients with advanced STS is poor with a median overall survival of approximately 18 months. Furthermore, historically the treatment options for patients with advanced disease have been limited. The introduction of imatinib and other targeted therapies in gastro intestinal stromal tumours has in many ways been

There were also secondary endpoints to the study that focused on progression-free survival, time before progression, tumor response rate overall, length of response and safety. The primary and secondary endpoints were followed until patient death, loss to follow-up, or end of study (Trastuzumab).

Phase I clinical trials of Imatinib began in 1998 with the intention to determine the maximally tolerated dose. Chronic CML patients who did not respond to a current chemotherapy for CML, interferon- (IFN), were used. Though the maximally tolerated dose was not identified, remarkably, 53 of the 54 patients showed hematologic responses even though they were already in the chronic stages of CML (Deininger, Buchdunger and Druker, 2005). With such great results, phase II of Imatinib started in 1999. Imatinib was administered to patients in all stages of CML. Essentially, the results of this study backed up the results from phase I. However, this study showed a progression-free prognosis at 18 months in roughly 90% of patients. With both phase I and phase II, the Food and Drug Administration approved Imatinib for the treatment of CML in advanced stage patients, as well as, patients who had previously failed IFN (Deininger, Buchdunger and Druker, 2005).

In our study, serum level of IL-8 in NSCLC patients was significantly higher than controls (35, 36) which is consistent with other reports. IL-8 shows varation in cancerous cells that makes it worth biomarker.

Chemotherapy regimens vary based on the clinical status and medical history of patients. The objective of chemotherapy is to stabilize the normal blood cell counts and the normal hematopoiesis to be less than 5% blast cells in the bone marrow (Overview of Leukemia - Hematology and Oncology - Merck Manuals Professional Edition, “n.d.”). Moreover, chemotherapy targets to limit or elicit cloning of leukemic cells. Patients with bleeding, anemia, and neutropenia are provided with transfusion of platelets, RBCs, and granulocytes. Immunosuppressive and neutropenic patients are administered antimicrobials to prevent serious progression of infection. Under chemotherapy, patients can experience hyperuricemia, hyperphosphatemia, hypocalcemia, and hyperkalemia due to leukemic cell ruptures hence monitoring and providing hydration and electrolyte, and level of urine alkalinization is required. Furthermore, revival of leukemic cells in the bone marrow, the CNS, the testes, or other sites is threatening. Chemotherapy may not be most effective treatment or permanent cure. Therefore, stem cell transplantation offers effective and long-term cure if patient can find matching stem cells to be transferred. “Hematopoietic stem cell (HSC) transplantation is a rapidly evolving technique that offers a potential cure for hematologic cancers (leukemias, lymphomas, myeloma) and other hematologic disorders (eg, primary immunodeficiency, aplastic anemia, myelodysplasia).” (Hematopoietic Stem Cell Transplantation Leukemia - Hematology and Oncology - - Merck Manuals Professional Edition,